| INTRODUCTION
Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC) are chronic, disabling and progressive diseases involving mainly the gastrointestinal tract. 1 Patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM) in up to 50% of the cases. 2 EIM have a negative impact on the patient's quality of life and may interfere with treatment decision-making. [2] [3] [4] EIMs are more common in CD than UC and there is a broad range of manifestations. The most prevalent EIMs in IBD are arthralgia/arthritis and skin manifestations. 2, 4 Most
EIMs run in parallel with the intestinal disease activity but they may also have distinct course requiring multidisciplinary management.
Vedolizumab is a fully humanized monoclonal antibody that blocks specifically the migration of a subset of leucocytes arboring the a4b7 integrin into inflamed intestinal tissue. 5 The efficacy and safety of vedolizumab have been demonstrated in three pivotal phase 3 clinical trials, in patients with moderate-to-severe UC and CD, as induction and maintenance therapy. [6] [7] [8] The Real-World Effectiveness and Safety of Vedolizumab has been confirmed in prospective and retrospective cohorts of patients in routine practice. [9] [10] [11] [12] [13] The gut-specificity of vedolizumab makes questionable its efficacy for EIMs. 14 Interestingly, the presence of an active homing axis between the gut and inflamed joint has been reported in patients with ankylosing spondylitis through the presence of cells expressing the a4b7 integrin in the inflamed joints and the upregulation of MadCAM-1 in the endothelium. [15] [16] [17] [18] The efficacy of vedolizumab for EIMs in IBD is unknown.
The French observatory on effectiveness and safety of vedolizumab in patients with inflammatory bowel disease (OBSERV-IBD) study has included all consecutive IBD patients who were treated with vedolizumab for active UC and CD between June and December 2014. Here, we evaluated for the first time the effectiveness of vedolizumab therapy on EIMs in patients with active UC and CD treated with vedolizumab in the OBSERV-IBD cohort and we looked at predictors of success.
| PATIENTS AND METHODS

| Study population
Between June and December 2014, 294 patients with active IBD including 173 patients with active CD (Harvey-Bradshaw Index (HBI) ≥ 6) and 121 with active UC (partial Mayo score > 4) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or at least one anti-TNF agent and who were treated with vedolizumab were included in a French national multicentre cohort study (OBSERV-IBD). 13, 19 Patients were followed from the first infusion at week 0 through week 54. Each patient received written information concerning the product. Physicians were committed by the French regulatory authorities to collect efficacy and safety information on a prospective basis independently from any commercial entity. Exclusion criteria included unclassified colitis, EIM without significant IBD activity as the initial indication for vedolizumab, prevention of CD postoperative recurrence, an ostomy and pregnancy or lactation. The protocol was approved by ethics committee (CCTIRS N°15.403).
Vedolizumab was administered intravenously at a dose of 300 mg at weeks 0, 2 and 6 as induction therapy and then at a dose of 300 mg every 8 weeks as maintenance therapy. [6] [7] [8] The concomitant use of steroids and/or immunomodulators was allowed according to investigator's decision and was recorded at every visit.
Optimization of vedolizumab therapy at a dose of 300 mg every four weeks was also allowed in case of insufficient response to vedolizumab therapy according to investigator's decision. 
| Data collection
| Statistical analysis
All included patients were evaluated from the inclusion at week 0 visit through week 54. All analyses were performed on an intent-totreat manner. The data are expressed as a number (%) for qualitative data and as a mean AE the standard deviation (SD) or median [in-
terquartile range] for quantitative data. The proportions of patients with no improvement, partial response and complete remission of EIMs, were compared at every time point using Chi-square test, without correction for multiple testing. The proportions of patients who met the criteria for the latter end points during the follow-up period were computed relatively to the whole population included at week 0. To identify predictors of complete remission of EIM, univariate analysis using the chi-square test and then multivariate analysis using binary logistic regression models were then applied and adjusted to the above-mentioned variables with an ascending stepwise procedure using Wald test. The EIM-free survival was calculated using the Kaplan-Meier method in patients without EIM at the time of inclusion. The survival distributions were compared using the log-rank test. To identify the independent factors, a Cox proportional hazard model was adjusted with an ascending stepwise procedure.
Variables with P < .10 in univariate analysis were considered to be potential adjustment variables for the multivariate analysis. Quantitative values were converted to qualitative values by dichotomy from median value in two distinct groups of equal sizes. Variables with P < .10 in univariate analysis were considered to be potential adjustment variables for the multivariate analysis. All analyses were twotailed, and p values less than 0.05 were considered significant. All statistical evaluations were performed using SPSS statistical software (SPSS Inc., v17, Chicago, IL, USA). All authors had access to the study data and had reviewed and approved the final manuscript.
3 | RESULTS
| Study population
A total of 294 patients with IBD were enrolled in the OBSERV-IBD cohort study and were treated with vedolizumab therapy ( Figure S1 ).
The demographic and clinical characteristics and medication history at week 0 of the 294 patients who were enrolled in the OBSERV-IBD cohort study are listed in Table S1 . Two hundred seventy-two patients completed the whole induction period and were evaluated at week 14 whereas 22 discontinued vedolizumab between Week 0 and week 14 for primary nonresponse in 18 cases, infusion-related in two and infectious adverse events in two. Thirty-five patients discontinued vedolizumab immediately after the week 14 visit while 237 were enrolled in the maintenance period. At week 54, 166
patients (94 patients in the CD group and 72 in the UC group) were still treated with vedolizumab maintenance therapy while 71 patients discontinued vedolizumab between week 14 and week 54 for lack of response in 67 cases, pregnancy in three and loss of follow-up in one. The outcome measures of efficacy of vedolizumab therapy at every time point from week 6 to week 54 are listed in Table S2 .
| Impact of vedolizumab therapy on extra-
intestinal manifestations present at baseline Table 1 . The presence of inflammatory arthralgia/arthritis at baseline was significantly associated with female gender, uncomplicated
Crohn's disease and a past history of paradoxical manifestations upon previous anti-TNF therapy.
Cutaneous EIMs included erythema nodosum in two cases, pyoderma gangrenosum in one, and necrotizing vasculitis in one patient.
Impact of vedolizumab on inflammatory arthralgia/arthritis present at baseline from week 6 to week 54 is presented in Figure 1 . (Table S3) .
Considering cutaneous EIMs, one patients experienced complete remission at week 54. The patient with pyoderma gangrenosum did not experience any improvement of the skin lesion and discontinued vedolizumab after the week 22 visit.
Considering aphthous stomatitis, one patient experienced complete remission from week 14 to week 54. The only patient with refractory aphthous stomatitis also had refractory Crohn's disease with primary nonresponse to vedolizumab therapy. She discontinued vedolizumab therapy at week 6 and was treated with ustekinumab.
| Incident cases of extra-intestinal manifestation during vedolizumab therapy
After excluding the 47 patients with inflammatory arthralgia/arthritis at baseline, inflammatory arthralgia/arthritis was observed in 34 patients (13.8%) of whom 17 (50%) were in clinical remission of IBD as defined by HBI or partial Mayo Clinic score. Nine patients had a prior diagnosis of ankylosing spondylitis and one had a prior diagnosis of thaumatological paradoxical manifestation. 23 Two patients had cutaneous paradoxical manifestations simultaneously to inflammatory arthralgia/arthritis. The latter patient had discontinued certolizumab pegol as third-line anti-TNF therapy after developing peripheral inflammatory arthralgia associated with an elevated titre of With the exception of the occurrence of episcleritis in one patient, no other EIM was reported during the follow-up period. Two decades after the introduction of anti-TNF agents, it is now widely accepted that paradoxical inflammation especially in the skin and the joints may appear upon anti-TNF therapy. [38] [39] [40] [41] The cause of these manifestations is still intriguing as they may appear independently of the pharmacokinetic and immunogenicity of the drug. The high frequency of antinuclear and anti-double stranded DNA antibodies suggest that autoimmune mechanisms may be involved. 27, 42 Paradoxical inflammation is considered as a drug-class effect of anti-TNF agents and is usually reversible upon drug cessation. 2 In the present study, cutaneous paradoxical manifestation was observed in 14 (4.8%) patients during the 54-week follow-up period and was in line with characteristics observed with anti-TNF agents. 38, 39 Recently, paradoxical inflammation of the skin has also been reported in patients treated with ustekinumab, a drug frequently used to treat cutaneous paradoxical manifestations. [43] [44] [45] [46] [47] Although it
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is conceivable that such manifestation may be related to intestinal activity of IBD or cutaneous infection, paradoxical inflammation may be not restricted to the anti-TNF drug class and should be assessed with other biological agents. 
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